Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.
Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced that it will release its third-quarter financial results on November 9, 2021, after the market closes. The company will hold a conference call at 5:00 p.m. ET the same day to discuss these results and provide updates on corporate developments. Participation can be done via a dedicated phone line and a live webcast will be available on their investor relations website. Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical biologics.
Organogenesis Holdings has announced their participation in two significant investor conferences. The management will engage in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14th at 1:15 p.m. ET. Additionally, they will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20th at 3:45 p.m. ET. Live audio webcasts will be available on their website, with replays accessible for 30 days post-conference.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has partnered with Net Health to become the first to utilize Net Health's CTP Connections Module, enabling the electronic submission of insurance benefits verification forms. This initiative aims to enhance efficiency for hospital and outpatient wound care providers in verifying benefits for Organogenesis's cell and tissue-based products. The service is provided at no extra cost to Net Health Wound Care users, minimizing administrative errors and speeding up responses from payors, ultimately improving patient access to critical products.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported robust financial results for Q2 2021, with net revenue reaching $123.2 million, a 79% increase year-over-year. Key drivers included Advanced Wound Care products at $111.4 million (up 87%) and Surgical & Sports Medicine at $11.8 million (up 27%). The company achieved a net income of $20.7 million, reversing a loss of $5.2 million in Q2 2020. Adjusted EBITDA increased to $25.1 million, or 20.4% of net revenue, compared to $0.3 million in the prior year.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced a new credit agreement with Silicon Valley Bank, introducing a $200 million credit facility. This includes a $75 million term loan and a $125 million revolving credit line, aimed at general corporate purposes and repaying an existing $100 million facility. Senior VP Henry Hagopian emphasized that this agreement will lower borrowing costs and support long-term growth. The partnership reflects the bank's commitment to the company’s innovation in advanced healing solutions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) plans to release its second-quarter fiscal year 2021 financial results on August 9, after market close. The management will host a conference call at 5:00 p.m. ET on the same day to discuss the results, followed by a Q&A session. Interested participants can join the call via phone or through a live webcast available on the company's investor relations website. A replay will be accessible for two weeks post-call. Organogenesis specializes in regenerative medicine focused on advanced wound care and surgical solutions.
Crocs Inc. (CROX) is set to replace Cantel Medical Corp. (CMD) in the S&P MidCap 400, effective June 2, 2021. Concurrently, Organogenesis Holdings Inc. (ORGO) will take Crocs' place in the S&P SmallCap 600. This change is part of an acquisition by STERIS plc of Cantel Medical, which is anticipated to conclude soon pending final conditions. This move reflects Crocs' growing presence in the market and the dynamics of index composition.
Summary not available.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported robust financial results for Q1 2021, with net revenue of $102.6 million, a 66% increase from Q1 2020's $61.7 million. Advanced Wound Care products drove this growth, reaching $90.7 million (up 77%). The company achieved a net income of $9.9 million, a significant turnaround from the $16.3 million loss in the prior year. Operating income improved to $12.6 million. Looking ahead, net revenue guidance for 2021 is set between $438 million and $454 million, projecting a 29% to 34% increase year-over-year.
Organogenesis Holdings Inc. (Nasdaq: ORGO) appointed Jon Giacomin to its Board of Directors, effective May 7, 2021, following Wayne Mackie's resignation on the same day. Giacomin brings nearly 30 years of healthcare experience, previously serving as CEO of U.S. Anesthesia Partners and Cardinal Health’s Medical Segment, which generated over $15 billion in revenue. This strategic leadership change aims to enhance the company’s growth potential as it continues to develop its regenerative medicine solutions in wound care and surgical markets.